抄録
To prevent adverse effects of heparin, new heparin free anticoagulant method for hemodialysis using ticlopidine was studied. Ticlopidine is a strong anti-platelet drug and suppresses platelet functions more powerfully than aspirin or dipyridamol.
In dog experiments, 150-200mg/kg of ticlopidine were given orally. Platelet aggregation rate reduced gradually and reached below 10% (1st phase of aggregation) or 35% (2nd phase) of pre-treated values after 10-12 hours. Thereafter, hemodialysis was performed for 2 hours. During hemodialysis, pressure differences between pre- and post-dialyser showed no elevation. Appearances of blood coagulation in dialyser after hemodialysis were as same as treated with heparin.
Thrombocytopenia during hemodialysis was more severe in heparin than ticlopidine. These results indicate that ticlopidine can be used as an anti-coagulant drug for hemodialysis. However, ticlopidine has shortages to act for longer time and to cause gastrointestinal symptomes such as anorexia or nausea in high dosage. So, for clinical usage, it is more preferrable to expect to reduce dosage of heparin.
